41,020 Shares in STERIS plc (NYSE:STE) Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB acquired a new position in shares of STERIS plc (NYSE:STE - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 41,020 shares of the medical equipment provider's stock, valued at approximately $9,949,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bleakley Financial Group LLC boosted its position in shares of STERIS by 8.7% during the 3rd quarter. Bleakley Financial Group LLC now owns 1,680 shares of the medical equipment provider's stock worth $407,000 after acquiring an additional 134 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of STERIS by 24.6% in the 3rd quarter. Assetmark Inc. now owns 13,410 shares of the medical equipment provider's stock valued at $3,252,000 after purchasing an additional 2,647 shares during the last quarter. KBC Group NV lifted its holdings in shares of STERIS by 52.0% in the 3rd quarter. KBC Group NV now owns 12,071 shares of the medical equipment provider's stock valued at $2,928,000 after purchasing an additional 4,132 shares during the last quarter. Foster Victor Wealth Advisors LLC lifted its holdings in shares of STERIS by 11.0% in the 2nd quarter. Foster Victor Wealth Advisors LLC now owns 60,302 shares of the medical equipment provider's stock valued at $13,727,000 after purchasing an additional 5,999 shares during the last quarter. Finally, LMR Partners LLP purchased a new stake in shares of STERIS in the 3rd quarter valued at about $1,473,000. 94.69% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. KeyCorp boosted their target price on STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. JMP Securities reissued a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Monday, November 18th. Stephens reissued an "overweight" rating and issued a $260.00 target price on shares of STERIS in a report on Thursday, November 7th. Piper Sandler raised STERIS from a "neutral" rating to an "overweight" rating and boosted their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of STERIS in a research note on Friday, November 8th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, STERIS has an average rating of "Moderate Buy" and a consensus price target of $262.50.

Insider Transactions at STERIS

In other news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the transaction, the senior vice president now directly owns 11,372 shares of the company's stock, valued at approximately $2,471,363.04. This represents a 12.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.14% of the company's stock.

STERIS Stock Performance

STE traded up $6.74 on Thursday, hitting $216.36. 690,405 shares of the company traded hands, compared to its average volume of 500,540. The company has a 50 day moving average of $221.14 and a 200-day moving average of $227.35. The company has a quick ratio of 1.55, a current ratio of 2.41 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $21.36 billion, a PE ratio of 49.40 and a beta of 0.83. STERIS plc has a 12-month low of $197.82 and a 12-month high of $248.24.

STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating the consensus estimate of $2.12 by $0.02. The firm had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm's revenue was up 7.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.03 EPS. Sell-side analysts anticipate that STERIS plc will post 9.1 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Stockholders of record on Tuesday, November 19th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.05%. The ex-dividend date is Tuesday, November 19th. STERIS's dividend payout ratio (DPR) is 52.05%.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.